Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex

Anastasios Gkountakos, Sara Pilotto, Andrea Mafficini, Caterina Vicentini, Michele Simbolo, Michele Milella, Giampaolo Tortora, Aldo Scarpa, Emilio Bria, Vincenzo Corbo

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Genomic alterations affecting components of the mechanistic target of rapamycin (mTOR) pathway are found rather frequently in cancers, suggesting that aberrant pathway activity is implicated in oncogenesis of different tumor types. mTOR functions as the core catalytic kinase of two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which control numerous vital cellular processes. There is growing evidence indicating that Rictor, an essential subunit of the mTORC2 complex, is inappropriately overexpressed across numerous cancer types and this is associated with poor survival. To date, the candidate mechanisms responsible for aberrant Rictor expression described in cancer are two: (i) gene amplification and (ii) epigenetic regulation, mainly by microRNAs. Moreover, different mTOR-independent Rictor-containing complexes with oncogenic role have been documented, revealing alternative routes of Rictor-driven tumorigenesis, but simultaneously, paving the way for identifying novel biomarkers and therapeutic targets. Here, we review the main preclinical and clinical data regarding the role of Rictor in carcinogenesis and metastatic behavior as well as the potentiality of its alteration as a target.

Original languageEnglish
Pages (from-to)971-980
Number of pages10
JournalCarcinogenesis
Volume39
Issue number8
DOIs
Publication statusPublished - Jul 30 2018

Fingerprint

Sirolimus
Carcinogenesis
Neoplasms
Gene Amplification
MicroRNAs
Epigenomics
Catalytic Domain
Phosphotransferases
Biomarkers
mechanistic target of rapamycin complex 1
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Gkountakos, A., Pilotto, S., Mafficini, A., Vicentini, C., Simbolo, M., Milella, M., ... Corbo, V. (2018). Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex. Carcinogenesis, 39(8), 971-980. https://doi.org/10.1093/carcin/bgy086

Unmasking the impact of Rictor in cancer : Novel insights of mTORC2 complex. / Gkountakos, Anastasios; Pilotto, Sara; Mafficini, Andrea; Vicentini, Caterina; Simbolo, Michele; Milella, Michele; Tortora, Giampaolo; Scarpa, Aldo; Bria, Emilio; Corbo, Vincenzo.

In: Carcinogenesis, Vol. 39, No. 8, 30.07.2018, p. 971-980.

Research output: Contribution to journalReview article

Gkountakos, A, Pilotto, S, Mafficini, A, Vicentini, C, Simbolo, M, Milella, M, Tortora, G, Scarpa, A, Bria, E & Corbo, V 2018, 'Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex', Carcinogenesis, vol. 39, no. 8, pp. 971-980. https://doi.org/10.1093/carcin/bgy086
Gkountakos A, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M et al. Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex. Carcinogenesis. 2018 Jul 30;39(8):971-980. https://doi.org/10.1093/carcin/bgy086
Gkountakos, Anastasios ; Pilotto, Sara ; Mafficini, Andrea ; Vicentini, Caterina ; Simbolo, Michele ; Milella, Michele ; Tortora, Giampaolo ; Scarpa, Aldo ; Bria, Emilio ; Corbo, Vincenzo. / Unmasking the impact of Rictor in cancer : Novel insights of mTORC2 complex. In: Carcinogenesis. 2018 ; Vol. 39, No. 8. pp. 971-980.
@article{0f983a11eff047c1beea9d224de94340,
title = "Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex",
abstract = "Genomic alterations affecting components of the mechanistic target of rapamycin (mTOR) pathway are found rather frequently in cancers, suggesting that aberrant pathway activity is implicated in oncogenesis of different tumor types. mTOR functions as the core catalytic kinase of two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which control numerous vital cellular processes. There is growing evidence indicating that Rictor, an essential subunit of the mTORC2 complex, is inappropriately overexpressed across numerous cancer types and this is associated with poor survival. To date, the candidate mechanisms responsible for aberrant Rictor expression described in cancer are two: (i) gene amplification and (ii) epigenetic regulation, mainly by microRNAs. Moreover, different mTOR-independent Rictor-containing complexes with oncogenic role have been documented, revealing alternative routes of Rictor-driven tumorigenesis, but simultaneously, paving the way for identifying novel biomarkers and therapeutic targets. Here, we review the main preclinical and clinical data regarding the role of Rictor in carcinogenesis and metastatic behavior as well as the potentiality of its alteration as a target.",
author = "Anastasios Gkountakos and Sara Pilotto and Andrea Mafficini and Caterina Vicentini and Michele Simbolo and Michele Milella and Giampaolo Tortora and Aldo Scarpa and Emilio Bria and Vincenzo Corbo",
year = "2018",
month = "7",
day = "30",
doi = "10.1093/carcin/bgy086",
language = "English",
volume = "39",
pages = "971--980",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Unmasking the impact of Rictor in cancer

T2 - Novel insights of mTORC2 complex

AU - Gkountakos, Anastasios

AU - Pilotto, Sara

AU - Mafficini, Andrea

AU - Vicentini, Caterina

AU - Simbolo, Michele

AU - Milella, Michele

AU - Tortora, Giampaolo

AU - Scarpa, Aldo

AU - Bria, Emilio

AU - Corbo, Vincenzo

PY - 2018/7/30

Y1 - 2018/7/30

N2 - Genomic alterations affecting components of the mechanistic target of rapamycin (mTOR) pathway are found rather frequently in cancers, suggesting that aberrant pathway activity is implicated in oncogenesis of different tumor types. mTOR functions as the core catalytic kinase of two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which control numerous vital cellular processes. There is growing evidence indicating that Rictor, an essential subunit of the mTORC2 complex, is inappropriately overexpressed across numerous cancer types and this is associated with poor survival. To date, the candidate mechanisms responsible for aberrant Rictor expression described in cancer are two: (i) gene amplification and (ii) epigenetic regulation, mainly by microRNAs. Moreover, different mTOR-independent Rictor-containing complexes with oncogenic role have been documented, revealing alternative routes of Rictor-driven tumorigenesis, but simultaneously, paving the way for identifying novel biomarkers and therapeutic targets. Here, we review the main preclinical and clinical data regarding the role of Rictor in carcinogenesis and metastatic behavior as well as the potentiality of its alteration as a target.

AB - Genomic alterations affecting components of the mechanistic target of rapamycin (mTOR) pathway are found rather frequently in cancers, suggesting that aberrant pathway activity is implicated in oncogenesis of different tumor types. mTOR functions as the core catalytic kinase of two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which control numerous vital cellular processes. There is growing evidence indicating that Rictor, an essential subunit of the mTORC2 complex, is inappropriately overexpressed across numerous cancer types and this is associated with poor survival. To date, the candidate mechanisms responsible for aberrant Rictor expression described in cancer are two: (i) gene amplification and (ii) epigenetic regulation, mainly by microRNAs. Moreover, different mTOR-independent Rictor-containing complexes with oncogenic role have been documented, revealing alternative routes of Rictor-driven tumorigenesis, but simultaneously, paving the way for identifying novel biomarkers and therapeutic targets. Here, we review the main preclinical and clinical data regarding the role of Rictor in carcinogenesis and metastatic behavior as well as the potentiality of its alteration as a target.

UR - http://www.scopus.com/inward/record.url?scp=85054973610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054973610&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgy086

DO - 10.1093/carcin/bgy086

M3 - Review article

AN - SCOPUS:85054973610

VL - 39

SP - 971

EP - 980

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 8

ER -